Innovative AI methodologies are transforming protein design and drug development. EMBL researchers introduced AlphaDesign, an AI framework advancing de novo protein creation with applications in therapeutics and precision medicine. Separately, University of Sheffield and AstraZeneca developed MapDiff, a machine learning system enhancing inverse protein folding accuracy for drug design. These advances promise to accelerate therapeutic discovery and protein engineering by improving structural precision and expanding design capabilities.